Scott Gottlieb
Showing 1–5 of 5 transcripts.
- Milken Institute34 min
A Conversation with Scott Gottlieb, Commissioner, U.S. Food and Drug Administration
Scott Gottlieb, Tanisha Carino, Michael Milken
The FDA is implementing a comprehensive strategic shift to accelerate drug approvals through digital health integration, organizational restructuring within the Office of New Drugs, and a transition to risk-based, post-market regulation for digital tools and manufacturing. This initiative aims to increase review productivity by 20%, publish hundreds of new guidances, and release detailed approval memos within 48 hours to enhance transparency while addressing pipeline disparities in rare versus common diseases. Concurrently, the agency prioritizes tobacco control through modified risk products and fosters market competition to lower drug costs, with Commissioner Gottlieb warning that ossified reimbursement models for novel therapies threaten future innovation if not adapted.
- Milken Institute35 min
A Conversation with FDA Commissioner Scott Gottlieb
Former FDA Commissioner Scott Gottlieb outlines a multifaceted regulatory strategy addressing the opioid epidemic, tobacco addiction, and the aftermath of Hurricane María on Puerto Rico's critical medical manufacturing sector. He emphasizes adapting regulatory frameworks for emerging technologies like artificial intelligence and digital health tools while prioritizing the prevention of medical misinformation and product shortages. The discussion highlights a shift toward reducing review cycles, de-risking early-stage development, and utilizing post-market surveillance to balance safety with innovation.
- Milken Institute48 min
A Conversation with FDA Commissioner Scott Gottlieb
Scott Gottlieb, Michael Milken, Indra Nooyi
This summit convened experts and FDA leadership to address critical public health challenges, including the link between sleep deprivation and obesity, the scaling of screen time interventions, and the opioid epidemic. Regulatory strategies were detailed for reducing opioid exposure through shorter prescription durations, while new tobacco policies aim to minimize nicotine addiction in combustible products and regulate youth-targeted vaping technologies. Additionally, the discussion covered FDA responses to supply chain disruptions in Puerto Rico following a hurricane and the development of regulatory frameworks for emerging digital health and artificial intelligence tools.
- Milken Institute1h 9m
A State of Emergency: Integrative Approaches to Addiction and the Opioid Epidemic
David Beier, Jerome Adams, Terry McAuliffe, Lori McFarling, Tom Moriarty, Nora Volkow, Tammy Wincup, Indra Nooyi, Scott Gottlieb
Federal and state leaders are mobilizing a multi-sector response to the opioid crisis, deploying 14,000 officials while partnering with organizations like CVS and Discovery Education to expand prevention education and pharmaceutical take-back programs. This coordinated strategy integrates clinical data, economic recovery initiatives, and new state-level regulations, such as Virginia's prescription limits, to address the 22% surge in overdose deaths and the underlying social determinants driving addiction. Stakeholders are urged to audit medicine cabinets and commit to shared resource distribution, aiming to transition from reactive emergency measures to proactive community resilience through improved health infrastructure and data analytics.
- Milken Institute24 min
The Future of Health: A New World of Collaboration
Ed Greissing, Michael Milken, Francis Collins, Lynn Goldman, Bob Hugin, Indra Nooyi, Scott Gottlieb
No substantive event occurred as the provided input contained only the repetitive word "you" and a single "Thank you." Consequently, no key figures, decisions, or actionable outcomes were identified to summarize. The transcript lacked any narrative arc, facts, or trends that could form the basis of a descriptive account.